This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic's (MDT) Midas Rex Drills Completes First U.S. Surgery
by Zacks Equity Research
Medtronic's (MDT) recent surgeries reach a milestone in the transformation of spine surgery as a result of increased accuracy and minimally invasive technique.
Why Medtronic (MDT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Lower Bulk Purchases May Weigh on Medtronic (MDT) Q3 Earnings
by Zacks Equity Research
Medtronic's (MDT) diabetes care, robotics surgery and neuromodulation lines are expected to have performed well in Q3.
The Zacks Analyst Blog Highlights: Oracle, Medtronic, Advanced Micro Devices, Intercontinental Exchange and First Republic Bank
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Medtronic, Advanced Micro Devices, Intercontinental Exchange and First Republic Bank
Top Stock Reports for Oracle, Medtronic & AMD
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Medtronic (MDT), and Advanced Micro Devices (AMD).
Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry
by Zacks Equity Research
Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.
Analysts Estimate Medtronic (MDT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accuray (ARAY) Releases Encouraging Breast Cancer Study Results
by Zacks Equity Research
Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.
Boston Scientific's (BSX) DBS System Gets FDA's Clearance
by Zacks Equity Research
The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
Haemonetics (HAE) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021
by Sriparna Ghosal
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently launched products as well as potential in its U.S. Surgical Support business.
Integra (IART) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Integra (IART) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
Medtronic (MDT) MITG Shows Fast Recovery Amid COVID-19 Woes
by Zacks Equity Research
Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.
Medtronic (MDT) Up 0.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Gets Canada Nod for Micra AV to Treat AV Block
by Zacks Equity Research
With the approval, Medtronic (MDT) aims to strengthen its Cardiac and Vascular Group business globally.
Medtronic (MDT) Releases Positive Study Results of RFA Therapy
by Zacks Equity Research
Medtronic's (MDT) OsteoCool RFA System is expected to provide better relief from debilitating pain for cancer patients.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market
by Zacks Equity Research
Medtronic's (MDT) Carpediem CRRT system compares favorably with the traditional three times a week therapy session.
Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus
by Zacks Equity Research
Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic
Medtronic (MDT) Shows Strong Sales Recovery Amid COVID-19 Crisis
by Zacks Equity Research
Based on the ongoing strong recovery in sales, Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.
Company News for Nov 25, 2020
by Zacks Equity Research
Companies in the news are: MDT, DLTR, J, SJM
Medtronic's (MDT) Q2 Earnings Beat Estimates, Margins Fall
by Urmimala Biswas
Deferred procedures due to the pandemic impact Medtronic's (MDT) Q2 performance.
Tandem Diabetes' (TNDM) Insulin Pump Approved by Health Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology cleared for use in Canada post the receipt of Health Canada approval.